Abstract
We attempted to identify deleted segments in two model tumor suppressor gene loci on chromosomes 13q14 and 17p13 that were associated with clonal expansion of in situ bladder preneoplasia using single nucleotide polymorphisms (SNPs)-based whole-organ histologic and genetic mapping. For mapping with SNPs, the sequence-based maps spanning approximately 27 and 5 Mb centered around RB1 and p53, respectively, were assembled. The integrated gene and SNP maps of the regions were used to select 661 and 960 SNPs, which were genotyped by pyrosequencing. Genotyping of SNPs was performed on DNA samples corresponding to histologic maps of the entire bladder mucosa in human cystectomy specimens with invasive urothelial carcinoma. By using this approach, we have identified deleted regions associated with clonal expansion of intraurothelial neoplasia; which ranged from 0.001 to 4.3?Mb (average 0.67?Mb) and formed clusters of discontinuous deleted segments. The high resolution of such maps is a prerequisite for future positional targeting of genes involved in early phases of bladder neoplasia. This approach also permits analysis of the overall genomic landscape of the involved region and discloses that a unique composition of noncoding DNA characterized by a high concentration of repetitive sequences may predispose to deletions.
Similar content being viewed by others
Main
Cancer develops via multiple, complex steps, many of which precede the development of microscopically recognizable preneoplastic conditions.1, 2, 3 Recent studies indicate that common human malignancies, including bladder cancer, begin as clonal in situ expansion of phenotypically normal cells, which may form large plaques involving the affected mucosa.4, 5 Identification of chromosomal regions and their target genes involved in the development of such clinically and microscopically occult preneoplastic lesions may provide valuable clues to the incipient events of human carcinogenesis.6, 7 Ultimately, the results could lead to the development of novel markers for early cancer detection and prevention.
We have previously reported the identification of several putative tumor suppressor gene loci involved in early preinvasive phases of human bladder cancer.8, 9, 10, 11 These loci were found by searching for allelic imbalances using DNA hypervariable markers and a whole-organ histologic and genetic mapping strategy developed in our laboratory. The ultimate identification of genes mapping to the deleted regions was hampered by the low resolution of the original recombination-based maps and the absence of continuous genome sequence maps, which were not available in the early phases of the human genome project.
In this paper, we present the strategy that combines whole-organ histologic maps and high-resolution genetic mapping using single nucleotide polymorphic (SNP) sites. It facilitates precise identification of deleted chromosomal regions and their positional candidate genes associated with growth advantage and clonal expansion of in situ preneoplasia.12, 13, 14 Here, we concentrate on the technological aspects of this approach referred to as high-resolution whole-organ mapping with SNPs and present the pattern of losses associated with clonal expansion of in situ bladder preneoplasia in two model tumor suppressor gene loci (RB1 and p53).
Methods
Whole-Organ Histologic and Genetic Mapping
Whole-organ histologic and genetic mapping was performed as described in our previous publications.8, 9, 10, 11 In brief, each fresh cystectomy specimen, taken from a patient who had bladder cancer, was opened longitudinally along the anterior wall of the bladder and pinned down to a paraffin block. The entire mucosa was divided into 1 × 2?cm rectangular samples and evaluated microscopically on frozen sections. The tissue of interest was microdissected from the frozen block, and cell suspensions were prepared by mechanically scraping the urothelial mucosa or gently shaking invasive tumor samples. Only those specimens that yielded more than 90% microscopically recognizable, intact urothelial, dysplasia of tumor were accepted for the study and used for DNA extraction. The intraurothelial precancerous changes were classified as mild, moderate, and severe dysplasia of carcinoma in situ. The tumors were classified according to the three-tier World Health Organization histological grading system and growth pattern (papillary vs nonpapillary).15 The depth of invasion was recorded according to the TNM (tumor–node–metastasis) staging system.16 In this report, we present the data using two whole maps of cystectomy specimens, which yield 62 and 40 DNA samples, respectively, and both contained microscopically normal urothelium, preneoplastic condition, in situ changes, and invasive cancer. In both maps, a single focus of grade 3 nonpapillary urothelial carcinoma invaded the muscularis propria and was accompanied by extensive in situ precancerous lesions ranging from mild dysplasia to carcinoma in situ.
Genotyping with SNPs
The positions of chromosomal regions associated with an in situ clonal expansion mapping to 13q14 and 17p13 were initially identified by the whole-organ histologic and genetic mapping strategy with microsatellite markers. The recombination-based deletional maps of these regions can be obtained at www.mdanderson.org/departments/genomemaps/. For high-resolution mapping with SNPs, the genome sequence maps spanning approximately 27 and 5?Mb, corresponding to microsatellite defined regions in 13q14 and 17p13, respectively, were assembled. The positions of all currently defined SNPs mapping within these regions (approximately 20?000 SNPs per region) were identified in the SNP database (http://www.ncbi.nlm.nih.gov/SNP) and integrated with the genome sequence maps. The integrated gene and SNP maps were used to select 661 SNPs mapping within a 27-Mb segment around RB1 and 960 SNPs mapping within a 5-Mb segment around p53.
SNPs were genotyped by pyrosequencing methods using an automatic pyrosequencing instrument PSQTM 96 (Pyrosequencing AB, Uppsala, Sweden).17, 18 In brief, genomic DNA fragments containing SNPs were amplified by PCR with one of each primer biotinylated at the 5′-end. Single-stranded DNA was isolated by streptavidin-coated magnetic beads (Dynabeads M280, Dynal, Oslo, Norway). The sequencing reaction mixture contained a single-stranded DNA with sequencing primer annealed, DNA polymerase, apyrase, luciferase, ATP sulfurylase, adenosine 5′-phosphosulfate, and luciferin. The PCR and sequencing reactions were performed on a TECAN robotic system (GENESIS workstation 150). The sequence was determined from the measured signal output of light upon nucleotide incorporation. The resulting peaks were analyzed using pyrosequencing software. A minimum 50% signal intensity reduction from one of the polymorphic nucleotides as compared to the nontumor DNA of the same individual was used to identify a haplotype defining allelic loss. The distributions of losses identified in individual mucosal samples for each SNP were subsequently superimposed over the histologic maps of the entire cystectomy specimen.
Analysis of SNP-Based Haplotype Distribution Patterns
The distribution patterns of allelic loss defined by SNP-based haplotypes in relation to the development and progression of in situ neoplasia were analyzed in superimposed whole-organ histologic and genetic maps by nearest neighbor and binomial maximum likelihood algorithms as previously described in detail.11 In brief, for statistical analyses, the data were organized in 2 × 4 contingency tables (fji, j=1, 2; i=1,…,4). The columns designated whether the marker retained or lost heterozygocity and the four grades represented the microscopic status of the urothelium (D0, normal urothelium, D1, low-grade intraurothelial neoplasia, D2, high-grade intraurothelial neoplasia, and D3, transitional cell carcinoma (TCC)). For statistical analysis, the intraurothelial precancerous changes were classified into two major groups: low-grade intraurothelial neoplasia (mild and moderate dysplasia, LGIN) and high-grade intraurothelial neoplasia (severe dysplasia and carcinoma in situ, HGIN).1
A nearest-neighbor analysis was performed on the three-dimensional stacks of maps consisting of plots with results of sequencing data for individual SNPs by location on the histologic bladder and genome sequence maps.19 A region with allelic loss was considered a neighbor of another region of allelic loss if the two were side by side in the same SNP plot or above and below each other. A region with allelic loss was also considered to be connected to another region with allelic loss if there was a continuous string of regions with allelic losses between them. Since the bladder was laid open and pinned flat, the left-most and right-most regions were also neighbors.
The binomial maximum likelihood analysis was performed in the same 2 × 4 contingency tables. The maximum likelihood of the binomial distribution was calculated for each SNP and urothelial status (Di, i=0,…,3) corresponding to normal urothelium (NU), LGIN, HGIN, and TCC. The maximum likelihood for the binomial distribution was used to determine whether a row of data was consistent with a hypothesis of an unchanged (retention of polymorphism) SNP by calculating the log likelihood with
for the null hypothesis H0, where θ=θi, and θ=f1i/(f1i+f2i) is the maximum likelihood estimate of SNP with retention of polymorphism. Two times the negative of the log likelihood, −2li, is asymptotically χ2 with 1 degree of freedom, χ2(1). This expression can be written as
where LOD(θ̂i:θi) is the LOD-score function evaluated at θI.20 Each row of the table for which −2li, has approximate χ2(1) can be tested separately (stringency level 1) or all rows for diagnosis Di and more advanced (Di,?…,?D3) can be combined (stringency level 2) to get
which is also χ2(1) after adjustment by 2?ln(10)= 4.605. Because the maximum likelihood estimates for the individual rows are usually different from each other, the sum of the LOD scores and the sum of the χ2's were greater than the combined statistics. A χ2 test for heterogeneity was appropriate to test the combined estimate. Usually θi=0.5 is used to test linkage in familial disorders with meiotic segregation of the phenotype.20 In reference to sporadic cancer and especially when populations of tested cells represent sequential stages of the process with mitotic transmission of the phenotype, the null hypothesis is more appropriately verified at θ differing from 0.5. For example, a value of 0.99 is more appropriate if the SNP retains polymorphism in the tissue, and a value of 0.01 is more appropriate for determining whether the SNP has lost polymorphism in the later stages of the process, that is, invasive carcinoma. The pattern of LOD scores≥3 at θ=0.01 or 0.99 and LOD scores<3 at θ=0.5 for the same SNP was significant. The strongest association between an SNP with loss of polymorphism and neoplasia is when a LOD score is ≥3 at θ=0.99 and 0.5 and <3 at θ=0.01. The use of binomial likelihood analysis and LOD scores in our study is not the same as that commonly used in linkage of familial genetic predispositions for diseases. Here it is intended to be used in its generic mathematical sense as likelihood tests of events.20
Analysis of Genome Sequences
We analyzed the genome sequences spanning the 27 and 4?Mb around RB1 and p53, respectively. The genomic maps contained the positions of all known and predicted genes, SNPs, and non-LTR repeats integrated with the positions of deleted regions defined by SNP-based haplotypes from superimposed whole-organ histologic and genetic maps. We concentrated on those deleted regions that showed association with an in situ clonal expansion of preneoplastic urothelial cells and analyzed their CpG island and gene contents as well as the frequency of non-LTR repeats.
First, visual investigations of genomic maps and deleted regions suggested that the segments of deletions associated with in situ clonal expansions may contain a high density of non-LTR repeats. In order to verify this observation, we started with the null hypothesis that location of the deletions was independent of the repeat sequences density. We tested this hypothesis by analyzing the densities of repeats at fixed width windows centered at the informative SNPs. The repeat sequences density was defined as the number of repeat sequences base pairs in a fixed width window. The width of this window was proportional to the spacing between informative SNPs. The median distance between informative SNPs of approximately 27?kB suggested an optimal window of 13.5?kB on either side of the informative SNP. In the second step, we ranked all repeat sequences according to the number of base pairs and Wilcoxon's test was used to analyze the difference in density of repeats around SNPs showing loss associated with plaque-like clonal expansion, SNPs showing scattered nonclonal pattern of loss and with informative SNPs showing retention of polymorphism. Similar analyses were performed to test the relationship between densities of CpG islands, gene content, and the pattern of allelic loss defined by SNPs (data not shown).
Results
For mapping with SNPs, the sequence-based maps spanning approximately 27 and 5?Mb centered around RB1 and p53, respectively, were assembled. The integrated gene and SNP maps of the regions were used to select 661 and 960 SNPs, which were genotyped by pyrosequencing. Genotyping of SNPs was performed in three sequential steps on DNA samples corresponding to histologic maps of the entire bladder mucosa in human cystectomy specimens with invasive urothelial carcinoma. Initially, all selected SNPs of normal genomic DNA were sequenced. In the next step, those SNPs that exhibited polymorphism were tested on representative DNA samples corresponding to invasive transitional cell carcinoma of the bladder (TCC). In the final step, those SNPs that showed allelic loss were tested on all mucosal samples of the same cystectomy specimen. The distribution of allelic loss for each SNP was subsequently superimposed over the histologic map of the entire organ. The borders of deleted segments were defined by the nearest flanking SNPs that retained polymorphism in all mucosal samples. The allelic loss was determined by the comparison of the sequences of the mucosal and tumor DNA samples to the sequences of nontumor DNA from the same patient. Clonal loss was defined as the loss of the same polymorphic nucleotide in multiple mucosal samples. Nonclonal loss was defined as the loss of signal interchangeably corresponding to both residues of the polymorphic SNP in different mucosal samples.
The initial testing of 661 and 960 SNPs of peripheral blood samples selected for mapping of 13q14 and 17p13 regions identified 101 and 187 polymorphic SNPs mapping to 27- and 4-Mb segments containing RB1 and p53, respectively. Subsequent testing of the informative polymorphic SNPs in representative DNA samples corresponding to invasive TCC identified 15 and 11 haplotypic SNPs defining allelic loss in 13q14 and 17p13, respectively. These SNPs were tested on all mucosal samples of two cystectomy specimens. By superimposing the distribution of allelic losses over histologic maps of the entire bladder mucosa, we identified two basic distribution patterns of losses: scattered and plaque-like (Figure 1). The scattered foci of allelic losses in individual samples of bladder mucosa were typically nonclonal and involved both polymorphic residues of the SNP. In contrast, plaque-like losses were clonal, involving large areas of bladder mucosa with various precancerous conditions and typically extending to normal appearing urothelium. Such large clonal plaques of allelic loss were statistically significantly associated with progression of in situ preneoplasia to invasive TCC as revealed by binomial likelihood analysis. This association implied that the loss was responsible for growth advantage, which resulted in in situ expansion of a preneoplastic clone. The deleted regions associated with clonal expansion spanned from 0.001 to 4.3?Mb (average 0.67?Mb) and formed clusters of discontinuously deleted segments separated by nondeleted regions (Figures 2 and 3). In some instances, the flanking SNPs disclosed allelic loss restricted to an individual mucosal sample, a reflection of the instability of regions contiguous to deleted segments (Figure 4).
A cluster of deletions associated with an in situ clonal expansion in 13q14 involved approximately 13.97?Mb and consisted of four deleted segments spanning 0.79, 0.68, 1.91, and 4.68?Mb. These segments contained 7, 8, 9, and 10 positional candidate genes, respectively, which might lead to a growth advantage for a preneoplastic clone. The model tumor suppressor gene RB1 mapped to the deleted segment between 46.35 and 47.03?Mb (Figure 5). A similar cluster of deletions that consisted of two deleted segments spanning 0.12 and 0.05?Mb was identified 0.8?Mb telomerically to p53 in the 17p13 region. These two segments contained 12 and five positional candidate genes, respectively, which might also be relevant for growth advantage of a preneoplastic clone.
Visually, the segments of deletions associated with growth advantage and in situ clonal expansion of preneoplastic urothelial cells contained a significantly higher concentration of repetitive sequences as compared to the nondeleted segments and deletions, which formed scattered nonclonal random mucosal foci (Figures 5 and 6). The statistical analysis confirmed this impression and disclosed that for chromosome 17 the segments of allelic loss associated with a plaque-like clonal expansion of preneoplastic clone involving large areas of bladder mucosa contained a significantly higher concentration of non-LTR repeats as compared to the regions with retention of polymorphism and regions, which showed nonclonal loss in the form of scattered independent foci (Table 1 and Figure 7). No such relationship could be found for allelic loss on chromosome 13. Similar analyses of CpG island and gene content did not reveal any relationship between their densities and positions of deleted segments (data not shown).
Discussion
Whole-organ histologic and genetic mapping facilitated the analysis of the relationship between allelic loss and disease development from morphologically normal urothelium through microscopically recognizable intraurothelial lesions to invasive disease in the entire mucosa of the resected organ. We precisely identified those losses that are associated with the in situ clonal expansion and are likely significant for the incipient phases of bladder carcinogenesis. Specifically, we identified clusters of discontinuous loss mapping to 13q14 and 17p13 containing model suppressor genes RB1 and p53. The high density of SNP markers permitted us to narrow the deleted segments from 4.6?Mb to below 0.1?Mb scale and disclosed that loses represented clusters of discontinuous segments ranging in size from 0.1 to 4.6?Mb separated by nondeleted regions.
The strategy presented here is not only important for identifying positional candidate genes that may provide growth advantage for a preneoplastic clone, but for also permiting the analysis of the overall genomic landscape of the involved regions. Such an analysis disclosed that the deleted regions associated with clonal expansion of preneoplasia contained a high concentration of repetitive sequences. This, in turn, suggests that the unique composition of noncoding DNA in the regions may predispose the genome to instability and allelic imbalance. The evidence provided by our study implies that the genes located in deleted regions may be responsible for growth advantage of in situ preneoplasia and the high content of repetitive sequences in these regions predisposed to deletions is circumstantial and has to be elucidated by functional studies. In summary, the strategy presented in this communication permits precise identification of deleted chromosomal regions associated with clonal expansion of preneoplasia. Such maps performed on a whole-genome scale will be critical for future specific studies on mechanisms initiating carcinogenesis.
References
Albores-Saavedra J . The Pathology of Incipient Neoplasia. Oxford University Press: New York, 2001.
Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111–116.
Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001;8:9–15.
Carethers JM . The cellular and molecular pathogenesis of colorectal cancer. Gastroenterol Clin North Am 1996;25:737–754.
Ilyas M, Straub J, Tomlinson IP, et al. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:1986–2002.
Czerniak B, Li L, Chaturvedi V, et al. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 2000;27:392–402.
Houlston RS, Peto J . The search for low-penetrance cancer susceptibility alleles. Oncogene 2004;23:6471–6476.
Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999;18:1185–1196.
Yoon DS, Li L, Zhang RD, et al. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Oncogene 2001;20:5005–5014.
Kram A, Li L, Zhang RD, et al. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest 2001;81:1039–1048.
Chaturvedi V, Li L, Hodges S, et al. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 1997;14:2059–2070.
Tong BC, Dhir K, Ha PK, et al. Use of single nucleotide polymorphism arrays to identify a novel region of loss on chromosome 6q in squamous cell carcinomas of the oral cavity. Head Neck 2004;26:345–352.
Zhou X, Li C, Mok SC, et al. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 2004;151:82–84.
Janne PA, Li C, Zhao X, et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004;23:2716–2726.
Mostofi F . HIstological Typing of Urinary Bladder Tumors, 2nd edn. Springer: Berlin, New York, 1999.
Sobin L, Wittekind C . TNM Classification of Malignant Tumors. John Wiley: New York, 1997.
Ronaghi M . Pyrosequencing for SNP genotyping. Methods Mol Biol 2003;212:189–195.
Ahmadian A, Gharizadeh B, Gustafsson AC, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000;280:103–110.
Hartigan J . Clustering Algorithms. John Wiley & Sons, Inc.: New York, 1975.
Ott J . Analysis of Human Genetic Linkage. Johns Hopkins University Press: Baltimore, 1991.
Acknowledgements
This work was supported by the National Institute of Health, UO1 CA85078 (BC), RO1 CA066723 (BC), and P50 CA91846 (Pr. 1, BC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuziak, T., Jeong, J., Majewski, T. et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest 85, 689–701 (2005). https://doi.org/10.1038/labinvest.3700270
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/labinvest.3700270
Keywords
This article is cited by
-
The origins of bladder cancer
Laboratory Investigation (2008)
-
Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia
Laboratory Investigation (2006)
-
Pathology as the enabler of human research
Laboratory Investigation (2005)